loading...

Atopic Dermatitis Control Tool (ADCT)

Sanofi Group; Regeneron Pharmaceuticals Inc

Distributed by Mapi Research Trust

ProQolid

Distributed by Mapi Research Trust

Basic description

  • Published in 2019
Authors

Sanofi Group; Regeneron Pharmaceuticals Inc

Copyright
© Atopic Dermatitis Control Tool_Version 1, 27 Nov 2018 Sanofi Group and Regeneron Pharmaceuticals Inc. All Rights Reserved.
Objective
To measure Atopic Dermatitis (AD) disease control
Therapeutic area
  • Skin and Connective Tissue Diseases
  • Immune System Diseases
  • Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Therapeutic indication

Dermatitis, Atopic

Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin. 2020;36(3):367-376 (Full text article)

Simpson E, Eckert L, Gadkari A, et al. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 2019 Nov 6;19(1):15 (Full text article)

Access this questionnaire

Please proceed below

Login SIGN up free

Contact and conditions of use

Authors

Sanofi Group; Regeneron Pharmaceuticals Inc

Contact information

Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66

Conditions of use

Students, physicians, clinical practice, academic users

The ADCT must be used under license. Note that even though it is under license, no license fees will be required.

You may access the questionnaire and/or its available translations directly (see tutorial). Should you not see the Download button, please contact us.

Healthcare organizations, commercial users & IT companies

The ADCT must be used under license. Note that even though it is under license, no license fees will be required.

Submit your request (see tutorial). Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Author Website(s)

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.

Languages

Original language(s)

  • English for the USA

Translations

The list of available translations is subject to constant changes and may not be exhaustive. It is provided for information only. Some recently produced translations may not be included in the list below yet. Please do check the status of available translations with Mapi Research Trust / the developers / copyright holders / distributors.

Also, the listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.

ADCT

Arabic for Israel*
Arabic for Kuwait*
Arabic for Saudi Arabia*
Arabic for the United Arab Emirates*
Bulgarian for Bulgaria*
Croatian for Croatia*
Czech for Czech Republic*
Danish for Denmark*
Dutch for Belgium (Flemish)*
Dutch for the Netherlands*
English for Australia*
English for Canada*
English for Ireland*
English for the UK*
Estonian for Estonia*
Finnish for Finland*
French for Belgium*
French for Canada*
French for France*
French for Switzerland*
German for Austria*
German for Germany*
German for Switzerland*
Greek for Greece*
Hebrew for Israel*
Hungarian for Hungary*
Italian for Italy*
Japanese for Japan*
Korean for South Korea*
Mandarin for China*
Mandarin for Taiwan*
Norwegian for Norway*
Polish for Poland*
Portuguese for Brazil*
Portuguese for Portugal*
Romanian for Romania*
Russian for Estonia*
Russian for Israel*
Russian for Russia*
Slovak for Slovakia*
Slovenian for Slovenia*
Spanish for Argentina*
Spanish for Colombia*
Spanish for Mexico*
Spanish for Spain*
Spanish for the USA*
Swedish for Finland*
Swedish for Sweden*
Turkish for Turkey*
* Performed by Mapi/ICON

The author has selected Mapi/ICON Language Services as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi/ICON Language Services

Academic Translation:

Not authorized

More information on translations

For information on, or permission to use the translations, please contact Mapi Research Trust

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us